Medical Economics June 29, 2022
Investors face an uphill task this year:Things have been difficult thus far but there will be selective opportunities to recover lost ground and perhaps record some gains this year.
www.medicaleconomics.com/view/seeking-alpha-premium
The stock market has retreated sharply this year and quite relentlessly over the past few months. Biotechs have been in retreat since late last year and the industry group is well into a deep bear market with valuations on the S&P Biotechnology Select Industry Index (XBI) slashed by over 60% from their highs. Investors face an uphill task this year:Things have been difficult thus far but there will be selective opportunities to recover lost ground and perhaps record some gains this year.
A deep decline
Biotech valuations have fallen precipitously...
Today's Sponsors
Today's Sponsor